Drug Profile

VBY 329

Alternative Names: VBY-329

Latest Information Update: 08 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Invivyd
Class Antivirals; Monoclonal antibodies
Mechanism of Action Viral fusion protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Respiratory syncytial virus infections

Most Recent Events

24 Nov 2025 Preclinical trials in Respiratory syncytial virus infections in USA (Parenteral)
24 Nov 2025 Invivyd announces its intention to file an IND application for Respiratory Syncytial Virus (RSV) infections in the second half of 2026.
24 Nov 2025 Pharmacodynamics data from a preclinical study in Respiratory Syncytial Virus (RSV) infections were released by Invivyd

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com